Palbociclib (PD-0332991) HCl

Licensed by Pfizer Catalog No.S1116

Palbociclib (PD-0332991) HCl Chemical Structure

Molecular Weight(MW): 483.99

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Size Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

9 Customer Reviews

  • PD-0332991 causes inhibition of proliferation of EAC cells in a dose-dependent manner. Western blots showing the phosphorylation status of pRB at Ser780 and Ser795 after incubation with 125 nmol/L PD-0332991 for 24 and 72 hours. Reduction in cyclin A expression and the expression of RB2 (p130) tumor suppressor 72 hours after PD-0332991 treatment are shown (bottom). Total pRB (RB1) and actin are loading controls and T293 cell lysate (293) is a positive control for total pRB and phospho-pRB (Ph-RB). E, anchorage-independent growth of the 3 cell lines in the presence or absence (Cnt) of 125 nmol/L PD-0332991 for 3 weeks.

    Clin Cancer Res 2011 17(13), 4513-22. Palbociclib (PD-0332991) HCl purchased from Selleck.

    b, c MelJuso cells were treated for 12–48 h with 1 µM Selumetinib or 5 µM Palbociclib and the cells were fixed, stained with propidium iodide and cell cycle distribution was determined by flow cytometry (b) and whole cell extracts were fractionated by SDS-PAGE, transferred onto PVDF membrane and immuno-blotted with the indicated antibodies (c). Data is from a single experiment representative of three separate experiments with similar results. The data in (b) are mean ± S.D. from a single experiment with three replicate dishes of cell per data point; similar results were obtained in two additional experiments

    Cell Mol Life Sci, 2016, 73(4):883-900. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • (A) Percentage of DN3a cells in S-phase (as gated on DAPI profile) from control (Zfp36l1/2fl/fl) and Zfp36l1/2fl/fl; CD2Cre (DCKO) mice, after 1 d of treatment with vector or palbociclib (drug).

    J Immunol, 2016, 197(7):2673-85. Palbociclib (PD-0332991) HCl purchased from Selleck.

     

    Patient tumor cell sensitivity to combinatorial treatment with histone deacetylase (HDAC)/cyclin-dependent kinase (CDK) inhibitors in 3-D culture. The effect of each drug or drug combination was assessed by fluorescent dye to identify live (green) and dead cells (red). Cells from breast reduction patients were used as non-cancer control in the assay.

    Pharmacogenomics J 2013 13(1), 94-104. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • The expression of respective proteins in CDK4/6-Rb-apoptosis pathway in cells was examined by Western blot after 3 days of palbociclib treatment.

    Biochim Biophys Acta, 2018, 1864(5 Pt A):1573-1582. Palbociclib (PD-0332991) HCl purchased from Selleck.

     

    Cdk4 is upregulated in ARMS and mMSCs transfected with PAX7-FKHR fusion gene (MP7F), and can be specifi cally inhibited. D: IF results showing overexpression of cdk4 in MP7F cells compared to parental mMSCs and reduced expression of cdk4 after treatment of MP7F cells with the cdk4 inhibitor, PD-0332991. E: IF results showing MyoD1 expression in parental mMSCs cells, and MP7F cells untreated and after treatment with the cdk4 inhibitor, PD-0332991.

    Clin Transl Oncol 2012 14(3), 197-206 . Palbociclib (PD-0332991) HCl purchased from Selleck.

  • WM3734 melanoma cells were treated by PD-0332991 for 36 hours; melanoma cells treated by Doxorubicin (DXR)  at 0.5 μM is included as a control.

     

     

    Dr. Gao Zhang of University of Pennsylvania. Palbociclib (PD-0332991) HCl purchased from Selleck.

    Serum-deprived T98G glioma cells are restimulated with serum(FBS) with or without 1 μΜ PD-0332991.

     

     

    Dr. Sabine Paternot and Dr Pierre Roger of IRIBHM, ULB, Brussels. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • P16INK4A knockdown in INK4A/ARF-wt human glioma cell LN319 potentiates PDGF-Apromoted anchorage-dependent growth in vitro. Soft agar growth of Ink4a/Arf-deficient mAst and LN444 cells treated with PD0332991. (A) IB analysis. (B) Quantification of soft agar assays. β-actin was used as a loading control in all IB experiments. Data are presented as mean ± s.d. and representative of two independent experiments. **, P < 0.01; ***, P < 0.001

    Dr. Kun-Wei Liu from University of Pittsburgh. Palbociclib (PD-0332991) HCl purchased from Selleck.

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.
Features Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
Targets
CDK4/CyclinD3 [1]
(Cell-free assay)
CDK4/CyclinD1 [1]
(Cell-free assay)
CDK6/CyclinD2 [1]
(Cell-free assay)
9 nM 11 nM 15 nM
In vitro

PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser780. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. [1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. [2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. [3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLM13 NH;EUWJMcW6jc3WgRZN{[Xl? NVPUOW5jOjRiaB?= M1fGR2lvcGmkaYTpc44hd2ZiQ1TLOEBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJHJjKHCqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFIh|ryP MXuyOFY1OTFyMx?=
COLO205 MmfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUe3NkBp MnPqRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{\XO|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcO0ifdHj5cYllcW6nIHnueI8hTE6DIIfpeIghUUN3MDDv[kAxNjB|NjFOwG0> NEHIWWYzPDZ2MUGwNy=>
U937 M1\GbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vJPFczKGh? NGnKT|VCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMUSg{txO NHLE[XMzPDZ2MUGwNy=>
MOLM13 NFLCW2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;GWoE4OiCq NGfGb5pCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3PUG0yOyClZXzsd{Bp[XKkb4LpcochTkyWMzDJWGQhdXW2YX70JIF{e2W|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzOKXYTofY1q\GmwZTDpcpRwKESQQTD3bZRpKEmFNUCgc4YhOC5yOU[g{txO Mn\6NlQ3PDFzMEO=
MOLM13 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLqUIo4OiCq MVLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IIPvdoFn\W6rYj3y[ZNqe3SjboSgbJVu[W5iTV;MUVE{KGOnbHzzJIF{e2W|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzOKXYTofY1q\GmwZTDpcpRwKESQQTD3bZRpKEmFNUCgc4YhOC5yOU[g{txO MXOyOFY1OTFyMx?=
MDA-MB-435 MmHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XjbFI1KGh? MknvTWM2OD1yLkG2JO69VQ>? M1my[lE2QDBzOEOx
K562 NWLSO5FpS3m2b4TvfIlkKEG|c3H5 NID1eJk6PiCq NETET4RFVVOR M2Dy[mlEPTB;MjFOwG0> M{XhUFI1PDF5NU[2
DU145 NHrseo1EgXSxdH;4bYMhSXO|YYm= MmrQPVYhcA>? NF\xd41FVVOR Mnv1TWM2OD15LkWg{txO NVzFdGFuOjR2MUe1OlY>
MDA-MB-231 NVmzcZhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzLVIV2OSEQvF2= NELxeZUzPCCq NIXv[3NFVVOR NEO5PZFE\WyuIHP5Z4xmKGG{cnXzeEBie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzFicHjhd4U> NX[5UYZyOjR2MUe1OlY>
MCF7 M2KzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFr4fGUyKM7:TR?= MXOyOEBp MnHCSG1UVw>? MnzOR4VtdCCleXPs[UBienKnc4SgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIHH0JGcyKHCqYYPl MmTFNlQ1OTd3Nk[=
MCF7 MlXZT4lv[XOnIFHzd4F6 NVrGbXBlPSEQvF2= M3P3[|I1KGh? NEPOUIlFVVOR NW\yOlZqUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBETEt2L3P5Z4xqdkRzIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZicnX0bY5w[myjc4TvcYEheGixc4Doc5J6dGG2aX;uJIF1KFOncke4NC=> M4q1U|I1PDF5NU[2
MDA-MB-231 MnzOT4lv[XOnIFHzd4F6 NHz6UWk2KM7:TR?= NWLEOY5ZOjRiaB?= Mkj3SG1UVw>? M13rZmlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgR2RMPC:leXPsbY5FOSCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHKndHnuc4Jt[XO2b33hJJBpd3OyaH;yfYxifGmxbjDheEBU\XJ5OEC= MYCyOFQyPzV4Nh?=
MDA-MB-231 M1nQbmZ2dmO2aX;uJGF{e2G7 NGO3N4EyNTFyIN88US=> MXiyOEBp NHPQVFVFVVOR NESzNnRld2W|IH7veEBqdmS3Y3WgZZBweHSxc3nzJIF{e2W|c3XkJIF{KFCDUmCgZ4xm[X[jZ3W= NHXNWHkzPDRzN{W2Oi=>
MCF7 MnfmSpVv[3Srb36gRZN{[Xl? M2\hOFEuOTBizszN NWjKUZhkOjRiaB?= NVHMeFFDTE2VTx?= MnP5[I9meyCwb4SgbY5lfWOnIHHwc5B1d3OrczDhd5Nme3OnZDDhd{BRSVKSIHPs[YF3[Wen NGjBb|kzPDRzN{W2Oi=>
MDA-MB-231 NWToXHdqTnWwY4Tpc44hSXO|YYm= Mn2wNE42NTFizszN MXe0PEBp MonSSG1UVw>? MmH2bIF{KG6xIFPlcIwh[3mlbHWgZZJz\XO2IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDzeYIuTzFicHjhd4U> Mnm0NlQ1OTd3Nk[=
MCF7 M{fsXWZ2dmO2aX;uJGF{e2G7 MYKwMlUuOSEQvF2= MmHhOFghcA>? MVPEUXNQ MV;oZZMhdm9iQ3XscEBkgWOuZTDhdpJme3RiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IIP1Zk1IOSCyaHHz[S=> NHO4b5UzPDRzN{W2Oi=>
697 M3:2Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTF2OD6zPEBvVQ>? NWixbIRVW0GQR1XS
P12-ICHIKAWA NGjoeopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nXZmlEPTB;OU[uNFQhdk1? MnT6V2FPT0WU
NB69 M3rJbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3G1fmlEPTB;MU[xMlghdk1? NVrVdo9XW0GQR1XS
EoL-1 M3zpUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;TZ2lEPTB;MUi3MlI3KG6P M13WSXNCVkeHUh?=
BHT-101 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHNd24zUUN3ME2xPVgvOjVibl2= MkTNV2FPT0WU
SK-NEP-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\oeGlEPTB;MkKwMlAzKG6P M4XQbHNCVkeHUh?=
MHH-NB-11 MmH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LIOGlEPTB;MkKwMlE6KG6P NWO3TGZHW0GQR1XS
AsPC-1 NXuwSJhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1y3[2lEPTB;MkWyMlU{KG6P NWfJWYJ7W0GQR1XS
ES1 M1:5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\HRoZiUUN3ME2yOVYvOjVibl2= MnLjV2FPT0WU
LAMA-84 M3fXUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfiPIhKSzVyPUK1PE4yQSCwTR?= MUTTRW5ITVJ?
MOLT-16 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTJ3OD60PUBvVQ>? Ml3tV2FPT0WU
ES7 NYDCO45qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTJ5Mz6wPUBvVQ>? NWDucIw5W0GQR1XS
KY821 NGj0eFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\3TWM2OD1|MUSuNUBvVQ>? MmXHV2FPT0WU
RT-112 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDaTWM2OD1|MkGuNFUhdk1? MWTTRW5ITVJ?
HL-60 NVKwRVdpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfQTWM2OD1|NECuOlYhdk1? NHTEd2JUSU6JRWK=
MOLT-4 NVvBO|FZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XtWmlEPTB;M{S1MlE{KG6P MnjDV2FPT0WU
KARPAS-45 M{fLd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\yUWlEPTB;M{e2MlE3KG6P M1PmWHNCVkeHUh?=
SK-N-AS NHmx[JpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTN6Nz64N{BvVQ>? MX7TRW5ITVJ?
CTB-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{[2cWlEPTB;NEC1MlAzKG6P MVfTRW5ITVJ?
NKM-1 NX;IOms5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7YTWM2OD12MUGuPFkhdk1? MVXTRW5ITVJ?
HTC-C3 M37hc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTR|Mj65OUBvVQ>? MnOxV2FPT0WU
BE-13 M4HNN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmi4TWM2OD12NESuNlchdk1? MX\TRW5ITVJ?
KOSC-2 M{XxfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnu3TWM2OD12Nk[uPUBvVQ>? NHixUJdUSU6JRWK=
NB14 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXy2UYlDUUN3ME20PFMvPThibl2= Mn\0V2FPT0WU
CAL-27 M3rJfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{L4[GlEPTB;NEm0MlU6KG6P Mn;KV2FPT0WU
H9 NH7zTFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfsTpFjUUN3ME20PVUvPDNibl2= NYK0ZpJuW0GQR1XS
RS4-11 NWL4S25FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknyTWM2OD13MESuO|Mhdk1? MVHTRW5ITVJ?
PA-1 NUnkUGZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PqSmlEPTB;NUC5Mlg3KG6P M2XPfXNCVkeHUh?=
MV-4-11 NEn6eXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTVzMz64OUBvVQ>? M{PxbnNCVkeHUh?=
OS-RC-2 MmDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\wcnNKSzVyPUWyNU43OiCwTR?= M2DC[3NCVkeHUh?=
RPMI-8226 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHjTJcyUUN3ME21NlYvQDZibl2= NIfUUZpUSU6JRWK=
HGC-27 MmHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTV4ND65PUBvVQ>? NEfsZ2tUSU6JRWK=
CHP-212 NISy[oFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TpVmlEPTB;NUmzMlU6KG6P NITCbVFUSU6JRWK=
NB10 NEPyUWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjVSoR{UUN3ME21PVkvOThibl2= MWjTRW5ITVJ?
HH MlHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTV7OT60N{BvVQ>? NUPrUYtXW0GQR1XS
EW-16 NVTVXo1CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTGZoNoUUN3ME22NFMvPTJibl2= MYfTRW5ITVJ?
ES8 NXe2dm5yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LGVWlEPTB;NkC1MlIyKG6P MUDTRW5ITVJ?
HAL-01 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfu[nRKSzVyPU[wOU43PyCwTR?= MmHtV2FPT0WU
A204 Mn;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFm1NHZKSzVyPU[zN{46OSCwTR?= NGfLUVhUSU6JRWK=
MHH-PREB-1 NFv6bJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXi1SXo6UUN3ME22N|YvQTlibl2= M{[xb3NCVkeHUh?=
EM-2 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTZ3MD62OEBvVQ>? NWjKTldDW0GQR1XS
BV-173 NVzoN3dkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoT0TWM2OD14NUKuOFghdk1? MmjMV2FPT0WU
ONS-76 MlPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLTNpdUUUN3ME22O|cvQDJibl2= NG[yS4JUSU6JRWK=
KM-H2 NVHDdJdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTZ7NT61OEBvVQ>? Mn;TV2FPT0WU
D-263MG NIHvTmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTdzNz6xNkBvVQ>? MoLmV2FPT0WU
ES3 NFrJbZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7nUHlKSzVyPUeyPE46OyCwTR?= MYrTRW5ITVJ?
VA-ES-BJ MoLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrhTWM2OD15M{KuNlchdk1? MWTTRW5ITVJ?
NBsusSR Mn;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVS0TpRyUUN3ME23OFIvQTlibl2= NU\vVXVRW0GQR1XS
NCI-H520 NXrqT2xRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3juO2lEPTB;N{S2MlUzKG6P MWDTRW5ITVJ?
ES5 NInrTYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILaU3FKSzVyPUe1Nk45KG6P NFzPSpZUSU6JRWK=
T-24 MnP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWP6OHpYUUN3ME23O|gvPzFibl2= M33oZXNCVkeHUh?=
SW962 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLNcZRKSzVyPUiwPE43OyCwTR?= MWnTRW5ITVJ?
EW-3 M4Cwe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGL3PGNKSzVyPUiwPE44PiCwTR?= NGf3fFBUSU6JRWK=
RXF393 MlTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2[yOGlEPTB;OEGyMlc6KG6P M2iyXXNCVkeHUh?=
U251 NInMZ|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVn0Wmo3UUN3ME24NVMvQDhibl2= NFfQ[45USU6JRWK=
CAMA-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTh|Mz65OEBvVQ>? MUXTRW5ITVJ?
JVM-3 NEn4V3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTh3MT63PEBvVQ>? MmS5V2FPT0WU
COLO-800 M2HPbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\mWGlEPTB;OEm3Mlc5KG6P MW\TRW5ITVJ?
OVCAR-5 M{nXSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlW2TWM2OD17MECuNUBvVQ>? MYrTRW5ITVJ?
LB1047-RCC MmnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2X4OWlEPTB;OUK3MlU3KG6P M4LodHNCVkeHUh?=
SW954 NET0U5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;HSpRKUUN3ME25NlkvPDFibl2= MUHTRW5ITVJ?
J-RT3-T3-5 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlznTWM2OD17M{[uNFYhdk1? NF\YPHlUSU6JRWK=
Mewo NEezeVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTl|Nj62JI5O MkXmV2FPT0WU
NCI-H1770 M3v2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7uNZlKSzVyPUm0NE42PSCwTR?= MnfmV2FPT0WU
HO-1-N-1 Mni1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTl4Mj64NUBvVQ>? M4fOfXNCVkeHUh?=
HSC-3 NWHmOm8zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTxTWM2OD17Nk[uOFghdk1? Mmj0V2FPT0WU
TYK-nu MoHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXm2cJBwUUN3ME25PVgvOjVibl2= NX:xbFBNW0GQR1XS
KYSE-150 NIfrcGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPHVHZlUUN3ME2xMlAxODd4IN88US=> NUnxbo1LW0GQR1XS
SN12C NIHiNWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nEXmlEPTB;MT6wNFg4PSEQvF2= MVTTRW5ITVJ?
MOLT-13 M1v0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHz[HRKSzVyPUGuNFE1OjFizszN MX3TRW5ITVJ?
TE-11 M2TWRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjNcItKSzVyPUGuNFQ5OTJizszN MnX5V2FPT0WU
DB MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTFwMEeyO|Mh|ryP M4jQSXNCVkeHUh?=
CAL-39 M{fCcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LkRWlEPTB;MT6wO|UzOiEQvF2= NX7rTZBSW0GQR1XS
A3-KAW MkW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTOTWM2OD1zLkC4OFA5KM7:TR?= NWjHdpVVW0GQR1XS
CHP-134 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Xk[2lEPTB;MT6xNVgxPyEQvF2= NETJOIRUSU6JRWK=
TGW MonWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vv[mlEPTB;MT6xNlM6PSEQvF2= NWrYOm5tW0GQR1XS
QIMR-WIL MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTFwMUOxN|Qh|ryP NVnaSmpzW0GQR1XS
NCI-SNU-1 NY[xNWd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTFwMU[zOVQh|ryP NIjEZY1USU6JRWK=
CGTH-W-1 NVLDTWgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XqNWlEPTB;MT6xO|E5PiEQvF2= NV:1ZZB[W0GQR1XS
MHH-ES-1 MknWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjPfI5KSzVyPUGuNVc6QDZizszN M3GwdnNCVkeHUh?=
LB2241-RCC MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHHTWM2OD1zLkG4OlIh|ryP Ml\3V2FPT0WU
ML-2 NWfqc5prT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;LNIdzUUN3ME2xMlIxPzN2IN88US=> MlT4V2FPT0WU
COR-L23 NXn4UJpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTFwMkK5N|Mh|ryP M2TGXnNCVkeHUh?=
BFTC-905 MnLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTFwMkSyOlch|ryP NUHaOnVvW0GQR1XS
Hs-578-T MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7RXXJOUUN3ME2xMlI2QDF5IN88US=> NEnXTm5USU6JRWK=
KG-1 NXvZ[3ZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TTfGlEPTB;MT6yOlY5PiEQvF2= NYLHNpBWW0GQR1XS
HEL M2\wdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTXWW5KSzVyPUGuNlk{OzhizszN NXvMcJlTW0GQR1XS
A549 NECyVm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvkRXFKSzVyPUGuNlk{QTlizszN Mn[5V2FPT0WU
COLO-741 M1TENGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DRZWlEPTB;MT6zNlA5QSEQvF2= NWDZc2lvW0GQR1XS
PC-3 NEDmOHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;uZWJKUUN3ME2xMlM2OjJzIN88US=> MnvrV2FPT0WU
HOS MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jTb2lEPTB;MT6zOVI6PiEQvF2= M2nHPHNCVkeHUh?=
HT-1080 NGTweYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\4PGlzUUN3ME2xMlM4PTF7IN88US=> MX;TRW5ITVJ?
TE-8 MnrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TTOmlEPTB;MT60NVc4PCEQvF2= NHfZeXBUSU6JRWK=
BHY M1[4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PIVWlEPTB;MT60OlkzOyEQvF2= MXzTRW5ITVJ?
BB65-RCC MkXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfG[VNKSzVyPUGuOVA2OjhizszN NUnFPWs6W0GQR1XS
HN NH\PVXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHjTWM2OD1zLkW0NFcyKM7:TR?= NFLBdZZUSU6JRWK=
NCI-H441 NFnpcIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4j6UGlEPTB;MT61OFkxPyEQvF2= MV7TRW5ITVJ?
RPMI-8866 NFnKbW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInJfG5KSzVyPUGuOVg2ODdizszN NFrRUYVUSU6JRWK=
CAL-62 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVj5ZoZJUUN3ME2xMlYxQDZ{IN88US=> MYPTRW5ITVJ?
MG-63 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPaVVhKSzVyPUGuOlE5OTNizszN NUCy[|JzW0GQR1XS
SK-LU-1 M1zhfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFP5cIxKSzVyPUGuOlIyPTJizszN NGKzc5pUSU6JRWK=
BCPAP MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3lcpZKSzVyPUGuOlY1PTdizszN NUfBVnZvW0GQR1XS
22RV1 Mlv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\0TWM2OD1zLk[3PFQ{KM7:TR?= Mn[0V2FPT0WU
T47D NYnwOHNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTFwNkiwOlEh|ryP NXHRWphPW0GQR1XS
MSTO-211H NV3oTHE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTFwNkm2NFMh|ryP M2fHenNCVkeHUh?=
DEL MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrRRnpKSzVyPUGuO|AzPzNizszN NIHKb4JUSU6JRWK=
H4 NGfJU21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XMd2lEPTB;MT63N|IyOiEQvF2= M3\NfnNCVkeHUh?=
CAL-51 MmHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYD2Ro42UUN3ME2xMlc1QDV3IN88US=> NU\ue41UW0GQR1XS
ABC-1 NX\3V4NwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjzSlVKSzVyPUGuO|g2QDJizszN M165TnNCVkeHUh?=
MZ2-MEL MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPTRYJpUUN3ME2xMlc6PTR{IN88US=> M3\JUHNCVkeHUh?=
YKG-1 NYHLVoVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\xTWM2OD1zLkixNFYyKM7:TR?= NX;BN20{W0GQR1XS
KM12 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIi1[plKSzVyPUGuPFE3ODJizszN NEnRWG1USU6JRWK=
L-363 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITwdFJKSzVyPUGuPFc1OTJizszN Ml62V2FPT0WU
KU812 Ml;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPTTlhFUUN3ME2xMlg6Ojh{IN88US=> MoPkV2FPT0WU
LOXIMVI MojVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTFwOUGyNlgh|ryP M{fIWXNCVkeHUh?=
G-401 NXHBWGxlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknITWM2OD1zLkmyOFI5KM7:TR?= NUDQOms4W0GQR1XS
SW780 M4SyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{npRmlEPTB;MT65OlI1PiEQvF2= NEX2VYRUSU6JRWK=
SW872 NGDpdnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIe1bVRKSzVyPUGuPVg{OyEQvF2= MX7TRW5ITVJ?
NB7 NUjkOpNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHCOFJKSzVyPUGuPVk{OjNizszN M2nZN3NCVkeHUh?=
T98G MkG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTJwMEC2OlYh|ryP M{D2SHNCVkeHUh?=
SW1710 M2TWb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXf1W3pbUUN3ME2yMlA3QTR3IN88US=> Mnj3V2FPT0WU
NCI-H1573 MmXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2D5[2lEPTB;Mj6wO|I6QCEQvF2= NG\UN3pUSU6JRWK=
KE-37 MnXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTJwMEi5OVEh|ryP NWTBcJVRW0GQR1XS
786-0 MmHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;meG8yUUN3ME2yMlE2PDN7IN88US=> NUHLWXpKW0GQR1XS
SAS NIrifnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTJwMkCzO|Qh|ryP MUfTRW5ITVJ?
CAL-54 M3q0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTJwMkC0NVMh|ryP M37TV3NCVkeHUh?=
SF268 NHvWfWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LKNWlEPTB;Mj6yN|EzOiEQvF2= M3G1RnNCVkeHUh?=
SW620 MnPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfkN2F1UUN3ME2yMlI3OTZ7IN88US=> MoPoV2FPT0WU
MN-60 MnXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DoW2lEPTB;Mj6zNVA3KM7:TR?= MoWxV2FPT0WU
EFO-27 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3q2emlEPTB;Mj6zNlA2QCEQvF2= M4HDWXNCVkeHUh?=
NCI-H747 MoXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HYdmlEPTB;Mj6zNlE6QSEQvF2= MnXqV2FPT0WU
HCC2218 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XFXmlEPTB;Mj6zOVM4PCEQvF2= MWDTRW5ITVJ?
MIA-PaCa-2 NVzjVpZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnP5TWM2OD1{LkO2OFM4KM7:TR?= NIDwT3lUSU6JRWK=
SJSA-1 MnHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;6TWM2OD1{LkO3O|k3KM7:TR?= MmW5V2FPT0WU
RKO NH\OUmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrPTWM2OD1{LkO4OFk3KM7:TR?= MVfTRW5ITVJ?
NB6 NVPLZXE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTJwNECzO|Qh|ryP NHvaO|VUSU6JRWK=
ES4 M3O2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrSS3B6UUN3ME2yMlQ2PDJ{IN88US=> MkKyV2FPT0WU
EGI-1 MljvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHjSnVKSzVyPUKuOFY5QDNizszN MnmyV2FPT0WU
CTV-1 NEK5UmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfhNY9KSzVyPUKuOVI4PzNizszN M3z1O3NCVkeHUh?=
NCI-H1355 M{n6N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTJwNUW5OVEh|ryP MWLTRW5ITVJ?
GT3TKB MmXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nGO2lEPTB;Mj61PVE6QSEQvF2= MmrGV2FPT0WU
SK-HEP-1 MoHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHNS3A4UUN3ME2yMlU6OjZ4IN88US=> NInrfZFUSU6JRWK=
GAMG M{P4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzXOXBLUUN3ME2yMlU6Ozl2IN88US=> NEe1WIdUSU6JRWK=
SK-MES-1 NUC0ZnFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTJwNkG4NFMh|ryP M2LsV3NCVkeHUh?=
RO82-W-1 NGCweFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33Fc2lEPTB;Mj62NlA2PyEQvF2= M4TB[HNCVkeHUh?=
ECC10 M4e4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIn0[mlKSzVyPUKuO|AzODZizszN NVv4Z4tUW0GQR1XS
MCF7 M173e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3w[pN7UUN3ME2yMlcyPDZ2IN88US=> NEjqXodUSU6JRWK=
D-283MED NVL0NI5[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLFfJRrUUN3ME2yMlczPDNizszN MVvTRW5ITVJ?
RPMI-7951 MojkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPNbJNKSzVyPUKuO|U3QTRizszN MVzTRW5ITVJ?
Ramos-2G6-4C10 MlrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTJwN{ewPVkh|ryP MoHoV2FPT0WU
KGN NEi5N5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTJwOEG4PFQh|ryP NX\3[nZYW0GQR1XS
NUGC-3 M1vG[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jBbWlEPTB;Mj64NlUxPSEQvF2= MlSwV2FPT0WU
NCI-H292 M13SN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYm2OVZMUUN3ME2yMlg2ODV|IN88US=> M3y4UXNCVkeHUh?=
Becker NGL4fYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LXO2lEPTB;Mj65OVg{OiEQvF2= MWDTRW5ITVJ?
NCI-H1299 NYLxVXZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jJS2lEPTB;Mz6wOVI3OyEQvF2= NYnLNYp6W0GQR1XS
ETK-1 NYLXW|IyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfKTlBKSzVyPUOuNFU1OyEQvF2= NIrNcXdUSU6JRWK=
TK10 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mne2TWM2OD1|LkKwNVY2KM7:TR?= MmDWV2FPT0WU
VMRC-RCZ NV\sZ2ZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Xj[GlEPTB;Mz6zOlQ5QCEQvF2= M1W4c3NCVkeHUh?=
YH-13 NVjseZpLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\GTWM2OD1|LkS0NFc6KM7:TR?= MnLhV2FPT0WU
DU-145 NX;qd2RKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTNwNE[yOlkh|ryP NIjuUmVUSU6JRWK=
SW1088 NVPuTI02T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTCTWM2OD1|LkS3OFch|ryP NXTiWlNLW0GQR1XS
HOP-92 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XGbmlEPTB;Mz61NFM1OiEQvF2= NFfqPXZUSU6JRWK=
KP-N-YS MnX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4K0V2lEPTB;Mz62NlE{QSEQvF2= MULTRW5ITVJ?
NCI-H460 M2PMemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELlSZBKSzVyPUOuOlY4OyEQvF2= MX3TRW5ITVJ?
U-2-OS M1LCVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTNwN{K1N|Uh|ryP MULTRW5ITVJ?
A101D NI[0RmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrsfIZKSzVyPUOuO|Y6OzZizszN NIq5epBUSU6JRWK=
MDA-MB-231 NF34dmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrsRlBxUUN3ME2zMlgyQTVzIN88US=> NYewNHJ6W0GQR1XS
IST-MES1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTNwOEOyJO69VQ>? M1;6UnNCVkeHUh?=
COR-L105 M4KzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEX6e|FKSzVyPUSuNFE5KM7:TR?= Mn7VV2FPT0WU
NCI-H1437 NVTP[Go6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjpfIx5UUN3ME20MlAzOzB{IN88US=> MXvTRW5ITVJ?
CAL-85-1 NIKyOlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTRwMEK0OlEh|ryP NXrrWWRKW0GQR1XS
MZ1-PC MlXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3EeVhKSzVyPUSuNVg2PTZizszN M{\kSXNCVkeHUh?=
VM-CUB-1 MmKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XFPWlEPTB;ND6zNVI5PCEQvF2= NGPFNJpUSU6JRWK=
CHL-1 NH\NUWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\wUpl4UUN3ME20MlMzOTZ7IN88US=> NI\XPW5USU6JRWK=
MDA-MB-361 M1jPeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzKTWM2OD12LkOzNVU{KM7:TR?= NEe4NIVUSU6JRWK=
NCI-H661 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XQXGlEPTB;ND61NFA6OiEQvF2= NVLkTmRUW0GQR1XS
EW-11 M4fFVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjUfXBIUUN3ME20MlUzOjNzIN88US=> NG\vfJVUSU6JRWK=
BEN NV7Qfok5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3uW3FGUUN3ME20MlUzQDF3IN88US=> MWPTRW5ITVJ?
BFTC-909 NVXwSZE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTRwNU[yO|Uh|ryP MkXwV2FPT0WU
NCI-H2087 MmH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLyR|dNUUN3ME20MlU5OTZ2IN88US=> MnLvV2FPT0WU
RVH-421 NG[xNZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1S4d2lEPTB;ND62OlY6KM7:TR?= Mm\oV2FPT0WU
P30-OHK MlXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTRwNkiwNFgh|ryP NVK1WmpIW0GQR1XS
NCI-H28 NYPxR5VVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3OybWlEPTB;ND64NVY3OSEQvF2= Mm\5V2FPT0WU
ES6 MnLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33tRWlEPTB;ND64N|AyPiEQvF2= NFzxeJBUSU6JRWK=
769-P MoTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTRwOEW5NlYh|ryP Mn[4V2FPT0WU
OE33 NFzZcWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7ROoc2UUN3ME20Mlg5OTZzIN88US=> NYXkW29CW0GQR1XS
SW982 M1[wUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPUe|VKSzVyPUSuPVUxPjFizszN NXv2eXVnW0GQR1XS
A388 NWH1XFlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTKNGR2UUN3ME21MlAzQTh|IN88US=> NGTIVoRUSU6JRWK=
TI-73 Mnf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTVwME[xPVQh|ryP MX3TRW5ITVJ?
HCT-116 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTEW3VKSzVyPUWuNFk5QDlizszN NULsZpJxW0GQR1XS
HuP-T3 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfPTWM2OD13LkG4O|A6KM7:TR?= M3vGcnNCVkeHUh?=
G-402 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPXTWM2OD13LkG5OFE3KM7:TR?= NVvt[m81W0GQR1XS
NCI-H1792 NGjs[pFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTzU5NKSzVyPUWuNlQ3OjJizszN MlPEV2FPT0WU
NCI-H209 M4HpPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7ES5pKSzVyPUWuNlU6PDJizszN MXrTRW5ITVJ?
NCI-H1650 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXPPW1KSzVyPUWuN|A3OzRizszN NGrQcYVUSU6JRWK=
LCLC-97TM1 M3LKR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fFUGlEPTB;NT6zNVgxQCEQvF2= M1nnbXNCVkeHUh?=
S-117 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGT0OVVKSzVyPUWuN|Y6PzZizszN NVTLOZpRW0GQR1XS
GI-ME-N NWXtSGdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDQTWM2OD13LkO5OlgyKM7:TR?= MV3TRW5ITVJ?
NCI-H2122 M4D4dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTVwNEmzPVch|ryP NVq2PXJwW0GQR1XS
NCI-H1793 NIGxeXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzYTWM2OD13Lk[3OVk{KM7:TR?= M4HlbHNCVkeHUh?=
C2BBe1 MnfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTWbXlNUUN3ME21MlcxODh6IN88US=> NF;INpdUSU6JRWK=
TE-12 MmrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTVwOEC1OVYh|ryP M17NfXNCVkeHUh?=
LCLC-103H NITX[I5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rreWlEPTB;NT65NVch|ryP M3X3THNCVkeHUh?=
A673 MnnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHBTWM2OD13LkmxPVMzKM7:TR?= NVv2SXJ4W0GQR1XS
BB30-HNC MkD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\iWpBKSzVyPUWuPVg{PiEQvF2= NYPqbIg4W0GQR1XS
SF295 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTZwMEC0NlIh|ryP NVvPNVlNW0GQR1XS
KU-19-19 NFSzOnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jxc2lEPTB;Nj6wNVc{OSEQvF2= NE[yVVhUSU6JRWK=
CFPAC-1 NH[zNZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjod2hKSzVyPU[uNFQ1PDNizszN M2e4ZXNCVkeHUh?=
LoVo NYHkNFNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PYUmlEPTB;Nj6wOVA3OyEQvF2= NXvCWpBzW0GQR1XS
8505C MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXjcXhKSzVyPU[uNFc2PzNizszN M{TPV3NCVkeHUh?=
GMS-10 Mny4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHsWG9KSzVyPU[uNVUxODJizszN NFXDTWZUSU6JRWK=
Ca9-22 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jYVGlEPTB;Nj6xOlcyKM7:TR?= M3fyVXNCVkeHUh?=
DOK NXiy[m5OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13yVWlEPTB;Nj6yNlA4OiEQvF2= MnLMV2FPT0WU
FADU NVX1V2pwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTZwMk[wN|kh|ryP NYGzOW5VW0GQR1XS
BxPC-3 M3XoV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fjUGlEPTB;Nj6yO|MzKM7:TR?= NY\weYRvW0GQR1XS
CAL-33 NXv4d3llT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLOSIhsUUN3ME22MlI6OjBzIN88US=> M{PHTXNCVkeHUh?=
SHP-77 NGfYZZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfxcFR3UUN3ME22MlMyPTF{IN88US=> MXzTRW5ITVJ?
LXF-289 Mlv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTZwM{O0OVUh|ryP NUTRWlhsW0GQR1XS
GB-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXQTWM2OD14LkO4NkDPxE1? MoPLV2FPT0WU
KS-1 NVvGdGI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDzdZJSUUN3ME22MlM5PDR5IN88US=> MVXTRW5ITVJ?
D-502MG NHGyd4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PJeWlEPTB;Nj60NlM4PiEQvF2= M4fvOHNCVkeHUh?=
LAN-6 M1rScGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPJRopkUUN3ME22MlUyODJ|IN88US=> M3zLdHNCVkeHUh?=
H-EMC-SS M4LBdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkL6TWM2OD14LkW2NVQ4KM7:TR?= MUfTRW5ITVJ?
LC-2-ad MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3TUXVMUUN3ME22MlYxODd4IN88US=> NX3WTppWW0GQR1XS
NCI-H1693 M2e3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHQTWM2OD14Lk[yNlE2KM7:TR?= MU\TRW5ITVJ?
SK-N-FI M1LRemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVK0cYtrUUN3ME22Mlc2ODR2IN88US=> MnfCV2FPT0WU
D-423MG MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonvTWM2OD14Lke2NVE4KM7:TR?= M1fDWnNCVkeHUh?=
KNS-42 MlfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTB[o1TUUN3ME22Mlc5OTl5IN88US=> M1PBW3NCVkeHUh?=
GCT NXvwV28yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrhTWM2OD14LkmzPEDPxE1? M3zUT3NCVkeHUh?=
DSH1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzZfoVKSzVyPUeuNFY{OyEQvF2= MoDyV2FPT0WU
D-247MG NGfFTGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULwTmUxUUN3ME23MlA4QDhzIN88US=> MoXpV2FPT0WU
NCI-SNU-5 MoLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTdwMUizO|Eh|ryP M17QU3NCVkeHUh?=
TE-6 M{f6NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTdwMkC2NFEh|ryP NVn0OoNsW0GQR1XS
NOMO-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvCPGZKSzVyPUeuNlIyOjdizszN NXPyPGxGW0GQR1XS
NB17 NF7zbWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PwXWlEPTB;Nz6zNFMxQSEQvF2= NGLwdZpUSU6JRWK=
EW-22 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjNcnhKSzVyPUeuN|Q{PDhizszN NYL0VmJiW0GQR1XS
EW-13 NGnaZW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4KyRWlEPTB;Nz6zOVE3OiEQvF2= NUGxeI45W0GQR1XS
DOHH-2 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfUTWM2OD15LkS0NFIh|ryP MX3TRW5ITVJ?
TGBC1TKB MnPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTdwNEm4PVkh|ryP NI\6[FFUSU6JRWK=
GR-ST M3n2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHFW21UUUN3ME23MlUzPTl2IN88US=> MojFV2FPT0WU
KYSE-520 Mlu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTdwNUW1NVUh|ryP NX2xWHJbW0GQR1XS
CAPAN-1 MkHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DiTWlEPTB;Nz61PVUyKM7:TR?= MVrTRW5ITVJ?
HCE-4 NIPqTFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTdwNkKyO|kh|ryP MXjTRW5ITVJ?
MLMA NEDDUHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjy[FZKSzVyPUeuOlI6PTdizszN NXm2[oZuW0GQR1XS
HT-144 M3PPfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXtTWM2OD15Lk[1N|Y5KM7:TR?= NWrNepVqW0GQR1XS
KYSE-180 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfMTWM2OD15LkexNVY6KM7:TR?= NHHFT|dUSU6JRWK=
TE-5 NIKzT4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvoTWM2OD15Lkm1PVcyKM7:TR?= NITNNGJUSU6JRWK=
IGROV-1 NFzwPXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTdwOUi1OVEh|ryP MmjKV2FPT0WU
NCI-H1581 Mn\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHT2Vo1KSzVyPUiuNFEzKM7:TR?= NFvLdpVUSU6JRWK=
SW1990 M13i[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jOVmlEPTB;OD6wOFY2QSEQvF2= NFHHPJdUSU6JRWK=
EFM-19 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\XTWM2OD16LkC4OVQ2KM7:TR?= MkXIV2FPT0WU
OGR-1 M3P2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRThwNEOwNlMh|ryP NFHiZnBUSU6JRWK=
U-118-MG NX\2TI06T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfvbpZnUUN3ME24MlQ{PDZ|IN88US=> MnftV2FPT0WU
SK-OV-3 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfoTWM2OD16LkS2O|Y2KM7:TR?= MmLUV2FPT0WU
KNS-62 M{ntemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3G1SmlEPTB;OD61NVc3OSEQvF2= MnPQV2FPT0WU
GOTO NH3qcGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnsWnJSUUN3ME24MlU4PjN3IN88US=> NEP6eJJUSU6JRWK=
8305C MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7XTWM2OD16LkewOFg1KM7:TR?= MXjTRW5ITVJ?
RPMI-2650 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;vdXhKSzVyPUiuO|E6PTVizszN MnTJV2FPT0WU
NEC8 NGHieXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HLTWlEPTB;OD63OFMxPyEQvF2= MWTTRW5ITVJ?
KYSE-450 NV72[GF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M370dGlEPTB;OD64OlU1QCEQvF2= NW\MSmFJW0GQR1XS
RMG-I MmnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljzTWM2OD17LkG0NFU5KM7:TR?= NH;rfotUSU6JRWK=
CAKI-1 NUnscHU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTlwM{G5O|kh|ryP MoW2V2FPT0WU
KYSE-510 MmS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPKeWVKSzVyPUmuN|U4PzhizszN M321NHNCVkeHUh?=
A4-Fuk M{\NSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXQOoFKSzVyPUmuN|Y4ODFizszN MWrTRW5ITVJ?
AN3-CA NEfiU5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHP1fHFKSzVyPUmuOFU1PDRizszN M3\mS3NCVkeHUh?=
SK-N-DZ NUKwfnZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXqW2UzUUN3ME25MlczQDR7IN88US=> Mn\mV2FPT0WU
HSC-2 M4XPOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrhOFVKSzVyPUmuO|Y3OjlizszN NEfWS2pUSU6JRWK=
EW-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmG5TWM2OD17Lke5N|Y6KM7:TR?= Mm\tV2FPT0WU
D-566MG NVXCU2tUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LD[WlEPTB;OT64N|Y3PCEQvF2= NYr5epJKW0GQR1XS
COLO-792 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXsTHFKSzVyPUmuPVg4PDZizszN NF\xSo9USU6JRWK=
TE-10 M{HVXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHkeXdKSzVyPUGwMlA{QTZizszN NEe5fZdUSU6JRWK=
NCI-H650 Mm\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELUdZJKSzVyPUGwMlQzQDZizszN Mlj5V2FPT0WU
U-266 Mle5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LhXmlEPTB;MUCuOFU2KM7:TR?= M3jIPXNCVkeHUh?=
Detroit562 NFvnU3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDi[JdVUUN3ME2xNU4xPTF3IN88US=> M4T5c3NCVkeHUh?=
NH-12 NFPGUIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoD4TWM2OD1zMT6xOFQ3KM7:TR?= NHTsbVVUSU6JRWK=
CO-314 MkixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTZVpVZUUN3ME2xNU4zQDR{IN88US=> MojNV2FPT0WU
IST-MEL1 MnXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEP6PJNKSzVyPUGxMlU{OjNizszN NUnCN21NW0GQR1XS
KNS-81-FD M362dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTFzLkW1Nlch|ryP NWjzVGZLW0GQR1XS
SW1463 M1;ZT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTFzLkW5PFkh|ryP NH3SRoZUSU6JRWK=
NCI-H23 M4L6V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTFzLk[1OVIh|ryP NVOzSZhLW0GQR1XS
SK-MEL-2 NV\FOWF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDt[XFbUUN3ME2xNU44OTl5IN88US=> MYrTRW5ITVJ?
NB13 NWPPU4JET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYX2ZllEUUN3ME2xNk4yPDl3IN88US=> M{nzOnNCVkeHUh?=
Daoy M2ntVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;VOmlEPTB;MUKuNlg2PiEQvF2= NUHPS5RUW0GQR1XS
NCI-H1623 M{LwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfYTWdKSzVyPUGyMlM5ODFizszN NUTU[VZpW0GQR1XS
NMC-G1 M1fyWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nETWlEPTB;MUKuO|E4KM7:TR?= NHvZXINUSU6JRWK=
DK-MG NV\kUnhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TQUWlEPTB;MUKuPVQ5OiEQvF2= MlPpV2FPT0WU
TCCSUP M{TKZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHwXJRKSzVyPUGzMlEzQDRizszN M2O3[HNCVkeHUh?=
SCC-15 NXPZV|hPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIraTGdKSzVyPUGzMlI3PTFizszN MVrTRW5ITVJ?
NOS-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlf1TWM2OD1zMz6yPFk{KM7:TR?= MnfSV2FPT0WU
RH-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULKbWxNUUN3ME2xN{4{ODN5IN88US=> NHOzS3ZUSU6JRWK=
SK-MEL-3 M{HQc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTF|LkO3Nlgh|ryP MV;TRW5ITVJ?
NB5 MmPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzDTWM2OD1zMz60NFY4KM7:TR?= MljjV2FPT0WU
SNU-387 NFTuT25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7qNphGUUN3ME2xN{42ODd{IN88US=> M2\XRXNCVkeHUh?=
CAL-120 MoPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLETWM2OD1zMz62O|E5KM7:TR?= MWHTRW5ITVJ?
Mo-T MkLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVm3dJV{UUN3ME2xN{44ODdizszN NEX3[W5USU6JRWK=
LNCaP-Clone-FGC NYLNZ3lVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{W4XWlEPTB;MUOuO|k6OiEQvF2= NVGxXGJkW0GQR1XS
CAN NETyVpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTF2LkCyPFgh|ryP MlS2V2FPT0WU
SK-MEL-30 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTF2LkC2N{DPxE1? MnfKV2FPT0WU
COLO-678 M1XVPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDhR5VFUUN3ME2xOE4xQDJ{IN88US=> NXjmUllmW0GQR1XS
SCC-9 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PIbGlEPTB;MUSuNVAzOSEQvF2= NULRd2pnW0GQR1XS
KINGS-1 NH;zXnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nNT2lEPTB;MUSuNVQxOiEQvF2= Ml7sV2FPT0WU
SL-513 MoPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\CSVNKSzVyPUG0MlE5PyEQvF2= NYfUVFYzW0GQR1XS
HLE NHfvSWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfQTWM2OD1zND6zPFUzKM7:TR?= NEHHN41USU6JRWK=
SW1573 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\tTWM2OD1zND60OFM2KM7:TR?= NYjkbnpCW0GQR1XS
KYSE-140 MlPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTF2Lk[zNlch|ryP NX\PVHZWW0GQR1XS
SK-PN-DW MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7FdFROUUN3ME2xOE45ODBzIN88US=> MV;TRW5ITVJ?
A253 M3mzUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTF3LkC2NlUh|ryP MXrTRW5ITVJ?
CAL-12T NVv4SVJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTTTWM2OD1zNT60OlYzKM7:TR?= M2LWbnNCVkeHUh?=
COLO-679 NVi0VVNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDYTWM2OD1zNT63Olg{KM7:TR?= NWTCVWdTW0GQR1XS
UACC-257 NWfFflFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHKxc2lKSzVyPUG2MlEzODFizszN NFrTNXRUSU6JRWK=
U-87-MG NYn1RnRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTF4LkO1NlMh|ryP MnLaV2FPT0WU
HCC1806 M{\Kc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjrfXlKSzVyPUG2MlcxPzFizszN MYrTRW5ITVJ?
NCI-H2170 NYjYd5ZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjFOYlWUUN3ME2xO{4zPDR6IN88US=> NHWxNFlUSU6JRWK=
AGS NIHXT2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDy[G0yUUN3ME2xO{4{QDB6IN88US=> MVTTRW5ITVJ?
MEL-HO M4XqUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jpUGlEPTB;MUeuO|UxOyEQvF2= Mn;2V2FPT0WU
SW48 MoTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\KZ2lEPTB;MUeuO|cyPiEQvF2= NYLUb2pSW0GQR1XS
HuP-T4 NVO2cGlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXL4WJZNUUN3ME2xPE4xOjB4IN88US=> Ml[3V2FPT0WU
NCI-H720 M{m4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;BcldRUUN3ME2xPE4yPDB{IN88US=> MVLTRW5ITVJ?
RCC10RGB NEDCR|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDJTWM2OD1zOD6xOlk4KM7:TR?= NVXWdnlzW0GQR1XS
HD-MY-Z Mn\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfoTWM2OD1zOD6yNlU1KM7:TR?= M{\YfXNCVkeHUh?=
A427 M13qemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDCTYp[UUN3ME2xPE42ODl2IN88US=> M1vWSnNCVkeHUh?=
HCC2998 MnzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4q0UWlEPTB;MUiuOlA2OSEQvF2= NVTjUJBEW0GQR1XS
EPLC-272H NXTFT2FKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4W2bmlEPTB;MUmuNFQ{PCEQvF2= Mn7FV2FPT0WU
C32 MofSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfjT3ZQUUN3ME2xPU4xPDVizszN MW\TRW5ITVJ?
UMC-11 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7MPJdKSzVyPUG5MlIyOjNizszN NXfxXG9NW0GQR1XS
CaR-1 M3jK[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\sTWM2OD1zOT62PFA1KM7:TR?= MoLFV2FPT0WU
KYSE-410 M2PGSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTF7LkmxN|kh|ryP MnzDV2FPT0WU
HuCCT1 NYLmToZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjLOpNRUUN3ME2yNE43Ojl2IN88US=> NXnmVllJW0GQR1XS
LB996-RCC M3jufmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjEZ5ZZUUN3ME2yNE44OTZ6IN88US=> NHz0[Y9USU6JRWK=
KYSE-70 NYDQ[lhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPMTWM2OD1{MD64NFU6KM7:TR?= NXXq[5ZpW0GQR1XS
CAL-72 MnnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTJyLkmxOUDPxE1? NH7YSmRUSU6JRWK=
Capan-2 NVLsTHlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTJzLkC0NVMh|ryP MmXuV2FPT0WU
PANC-08-13 NVvmboxIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rlemlEPTB;MkGuNlUyPSEQvF2= MmPtV2FPT0WU
SBC-1 NY\aXlNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPrWotjUUN3ME2yNU4{ODhzIN88US=> NFTmV3JUSU6JRWK=
MFM-223 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnwNphWUUN3ME2yNU4{OzR{IN88US=> MYHTRW5ITVJ?
BB49-HNC NV;Hbm1qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXhd4ZlUUN3ME2yNU42PzF4IN88US=> M1PVNHNCVkeHUh?=
SH-4 NInFboNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHqWpVjUUN3ME2yNU43PjF6IN88US=> NXu1enRqW0GQR1XS
HuO9 NXrRco5MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLVTWM2OD1{MT65PFI2KM7:TR?= M1Plc3NCVkeHUh?=
AM-38 MmHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjTeW1LUUN3ME2yNk4xPDh3IN88US=> Ml:wV2FPT0WU
A431 NXTzbJJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHyzPFdKSzVyPUKzMlIyOTlizszN NYHMcnBLW0GQR1XS
YAPC MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTJ|LkK2OVEh|ryP MojBV2FPT0WU
LU-139 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLMTWM2OD1{Mz60PFA6KM7:TR?= MmnOV2FPT0WU
HEC-1 NUP5SoViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTJ|LkS5N|ch|ryP MVPTRW5ITVJ?
SCC-25 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTJ2LkOwNFYh|ryP NILH[GtUSU6JRWK=
HT-29 MlvBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTtdmV7UUN3ME2yOE4{QDJ|IN88US=> NHzOepJUSU6JRWK=
PC-14 NV74dlUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\Hdm5KSzVyPUK0MlY2PzFizszN MYXTRW5ITVJ?
Calu-6 MmXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTFTWM2OD1{NT61NFcyKM7:TR?= M2KxV3NCVkeHUh?=
SJRH30 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYj0T|cyUUN3ME2yOU43PDl4IN88US=> M{PP[HNCVkeHUh?=
ChaGo-K-1 NF3TOYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTJ4LkG2Nlkh|ryP NX;nXFRpW0GQR1XS
IA-LM MnLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTJ4LkO2OFUh|ryP Mnq2V2FPT0WU
GP5d M3PXO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTJ4LkS0PVEh|ryP NGK5b|NUSU6JRWK=
NCI-H2291 NHHmVJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfvclF7UUN3ME2yOk43PTRzIN88US=> MnvMV2FPT0WU
BALL-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzOTWM2OD1{Nj65N|k4KM7:TR?= MoO2V2FPT0WU
HCC1954 NHTPU4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV6weo9xUUN3ME2yOk46QDB6IN88US=> Mn;MV2FPT0WU
NCI-H2452 NVfM[oszT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3T0OWlEPTB;MkeuOFE3OyEQvF2= MWPTRW5ITVJ?
LU-99A NGnLUFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3q3XmlEPTB;MkeuOVU5OiEQvF2= NGf2TGtUSU6JRWK=
NTERA-S-cl-D1 MnLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPjTWM2OD1{Nz63Nlk6KM7:TR?= MkOzV2FPT0WU
PANC-10-05 NYT4fZBxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljNTWM2OD1{Nz63O|c2KM7:TR?= M1\FeXNCVkeHUh?=
NCI-H2405 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTBTWM2OD1{Nz65N|g4KM7:TR?= MlrhV2FPT0WU
MDA-MB-415 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHRTWM2OD1{OD60NVM4KM7:TR?= M13Gc3NCVkeHUh?=
NCI-H2342 M{P4Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPOZWJKSzVyPUK4MlUzQDFizszN M3;Oe3NCVkeHUh?=
TGBC24TKB MonWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLhfWdGUUN3ME2yPE44OTF5IN88US=> MXXTRW5ITVJ?
LU-134-A MlHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLGTWM2OD1{OD65NlYyKM7:TR?= Mn;kV2FPT0WU
SCC-4 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLsWXBKSzVyPUOxMlA1QTRizszN NGHkXmZUSU6JRWK=
Saos-2 Mn;3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moi4TWM2OD1|MT65N|A3KM7:TR?= NHq0WZpUSU6JRWK=
RERF-LC-MS NI\sOpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3STWM2OD1|Mj64NlMyKM7:TR?= NUC3d4J4W0GQR1XS
M14 MlrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITYb|dKSzVyPUOyMlk4PjRizszN NWPjNnJ3W0GQR1XS
HPAF-II MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTN|LkWwNVEh|ryP Ml;LV2FPT0WU
NCI-H1755 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3X3ZmlEPTB;M{SuN|MxPSEQvF2= NWrNcFZVW0GQR1XS
D-392MG MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4q3U2lEPTB;M{WuPFY4PCEQvF2= NVvHVIpQW0GQR1XS
A704 MkD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfmT|BKSzVyPUO2MlA1OjdizszN MojMV2FPT0WU
CP50-MEL-B MlXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPlcII6UUN3ME2zOk4yQTFzIN88US=> NEHiWnhUSU6JRWK=
EW-18 NH3XUJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4e3TGlEPTB;M{[uOFUzKM7:TR?= MX\TRW5ITVJ?
WM-115 NWLlcXQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4j6TGlEPTB;M{[uPFA6QSEQvF2= MoDEV2FPT0WU
LU-65 MnTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonyTWM2OD1|Nz6xOFE4KM7:TR?= MULTRW5ITVJ?
NCI-H1563 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PneWlEPTB;M{euNlQ5PCEQvF2= NWHhN3Y4W0GQR1XS
DBTRG-05MG MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;BTWM2OD1|OD6wOlkyKM7:TR?= NHfySY5USU6JRWK=
NCI-H630 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljwTWM2OD1|OD60O|E1KM7:TR?= M3[1SnNCVkeHUh?=
NCI-H1155 MmfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTN7LkK0NkDPxE1? MYDTRW5ITVJ?
OVACR-3 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGric|FKSzVyPUO5MlkyQTVizszN MmPzV2FPT0WU
OAW-42 NVTOV4NtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjrWYFKSzVyPUSwMlQzPThizszN NHjmS4NUSU6JRWK=
JVM-2 M2fscmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDzNGFKSzVyPUSxMlI1OTVizszN NHPEOXBUSU6JRWK=
C3A M{XLXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfYXnZ3UUN3ME20NU4{PDR5IN88US=> Mmm2V2FPT0WU
HT55 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moi0TWM2OD12Mj6yPFQyKM7:TR?= MVnTRW5ITVJ?
OVCAR-4 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13NfmlEPTB;NEKuNlk4PCEQvF2= NHLifIpUSU6JRWK=
MEG-01 M{DkNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3:0WGlEPTB;NEKuOFYyPiEQvF2= MWHTRW5ITVJ?
NCI-H82 NFLEVZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTR|Lkm4PVIh|ryP MUnTRW5ITVJ?
JEG-3 M4HaeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnf4TWM2OD12ND65OFch|ryP NEOyZ25USU6JRWK=
BPH-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17WOGlEPTB;NE[uN|k6QCEQvF2= NUXZb3RmW0GQR1XS
MPP-89 NWfCPVBjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTR5LkK4PVgh|ryP Mni1V2FPT0WU
ALL-PO MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTR5LkSxPFgh|ryP MVvTRW5ITVJ?
HT MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonLTWM2OD12Nz60PVIh|ryP NXfDcmlpW0GQR1XS
NCI-H2347 NFPmNIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;KUnFKSzVyPUS4MlA4OTVizszN M2W0TnNCVkeHUh?=
A2780 M4HUVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTR7LkSyNlgh|ryP NYjsNnVLW0GQR1XS
KARPAS-299 M4PSUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzCSGFKSzVyPUS5MlUyOTlizszN NEjuUmNUSU6JRWK=
NCI-H1651 NFfDO5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzNbFlKSzVyPUS5Mlg5OjFizszN NIWyb3ZUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. [1]

Protocol

Kinase Assay:

[1]

+ Expand

Cdk Assays:

A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-32P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-32P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-32P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4  °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.
Cell Research:

[1]

+ Expand
  • Cell lines: Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562
  • Concentrations: 0.01-1 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are seeded at 2 × 104 per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [14C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice.
  • Formulation: Dissolved in sodium lactate buffer (50 mM, pH 4.0)
  • Dosages: 0-150 mg/kg
  • Administration: Given by gavage
    (Only for Reference)

Solubility (25°C)

In vitro Water 30 mg/mL (61.98 mM)
DMSO 3 mg/mL warmed (6.19 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
Saline
For best results, use promptly after mixing.
6 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 483.99
Formula

C24H29N7O2.HCl

CAS No. 827022-32-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03007979 Not yet recruiting Breast Cancer|Breast Carcinoma|Cancer of Breast|Malignant Tumor of Breast Washington University School of Medicine February 28, 2017 Phase 2
NCT02907918 Not yet recruiting Breast Cancer|Cancer of Breast|Breast Carcinoma Washington University School of Medicine|Pfizer February 28, 2017 Phase 2
NCT01209598 Completed Sarcoma|Liposarcoma Memorial Sloan Kettering Cancer Center|Pfizer September 23, 2010 Phase 2
NCT03054363 Not yet recruiting Breast Cancer University of Colorado, Denver March 2017 Phase 1|Phase 2
NCT03024489 Not yet recruiting Head and Neck Cancer|Locally Advanced|Unresectable Mahidol University February 2017 Phase 1|Phase 2
NCT02947685 Not yet recruiting HER-2 Positive Breast Cancer|Estrogen Receptor Positive Breast Cancer Alliance Foundation Trials, LLC.|Pfizer|German Breast Group (GBG)|Fondazione Michelangelo|PrECOG, LLC.|The Australia and New Zealand Breast Cancer Trials Group (ANZBCTG)|Alliance Foundation Trials Biorepository - Washington State University|Alliance Foundation Trials Central Imaging Core Lab - Ohio State University|Mastering Breast Cancer Initiative, LLC|Mayo Clinic Statistics and Data Center|INC Research|SOLTI Breast Cancer Research Group February 2017 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

Related CDK Products

Tags: buy Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl supplier | purchase Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl cost | Palbociclib (PD-0332991) HCl manufacturer | order Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID